XUND secures Pre-Series A: 6 million euros to strengthen European leadership in AI-powered healthcare
The investment, led by Lead Ventures and joined by J&T Ventures, strengthens XUND’s role in AI-powered healthcare. XUND will accelerate expansion in DACH and the UK, driven by increasing demand for certified solutions. By advancing MDR-certified solutions and aligning with the EU’s InvestAI initiative, XUND is shaping the future of AI-driven advancements in Europe.
Vienna-based healthtech scale-up XUND, which specializes in building industry-leading Software as a Medical Device (SaMD), has successfully closed a 6 million euro Pre-Series A funding round. The round will help accelerate XUND’s expansion across Europe, with a strategic focus on its core markets in DACH and the UK.
Strengthening XUND’s position in digital health
With new funding and an increasingly comprehensive portfolio of MDR-certified SaMD solutions, XUND is further strengthening its position as a homegrown European champion in digital health technology. With demand for AI-powered medical devices surging across the continent, XUND is well-positioned for rapid growth. Over the coming months, the company will accelerate its expansion in DACH and the UK, leveraging its MDR-certified technology to enable digital interactions from prevention to diagnosis.
Backed by leading investors
The investment round was led by Lead Ventures and joined by J&T Ventures, with continued support from existing investors MassMutual Ventures, tba network, and LANA Ventures, who reaffirmed their commitment to XUND’s mission and growth trajectory. “We are thrilled to partner with XUND, a company that brings clarity to the most important decisions in healthcare. Their commitment to digitizing the patient journey not only enhances patient care but also streamlines operations for healthcare providers. The long-anticipated synthesis of AI technology in patient care is finally happening widely and it is truly exciting to bring down the walls between new technologies and legacy healthcare systems. We have immense confidence in XUND's team and vision, and are eager to support their bold expansion efforts to transform healthcare delivery.” said Balázs Haszonics, Managing Partner at Lead Ventures.
David Polach, Partner at J&T Ventures: “The future of healthcare is not just digital — it’s intelligent, seamless, and deeply integrated. Our investment in XUND is driven by the thesis that AI-powered SaMD solutions will be the foundation of a more efficient, accessible, and data-driven healthcare system. What sets XUND apart is not only its world-class technology and the trust it has earned from some of the biggest names in healthcare but also the strength of its founding team and their bold vision. Their deep expertise, relentless execution, and commitment to transforming digital health give us full confidence that XUND is poised to become a global leader, redefining the future of healthcare at scale.”
Driving AI innovation in European healthcare
At the same time, XUND is consolidating its role as a critical infrastructure provider in Europe's evolving healthcare landscape — fully aligned with the EU's latest InvestAI initiative, which plans to mobilize 200 billion euros for investment in AI solutions that strengthen technological sovereignty. As Europe continues to advance its leadership in AI-driven healthcare, XUND is well-positioned to play a key role in shaping this transformation.
Tamás Petrovics, Co-Founder and CEO of XUND: “The latest investment is a testimony to the hard work of our team over the past years. It will help us accelerate our expansion across Europe while advancing the integration of our medical devices and RAVE, our cutting-edge large language model (LLM) solution. We are laying the foundation for a data-driven, personalized healthcare system that redefines how care is delivered — today and tomorrow.”